An ADC consisting of an anti-CD44 antibody (Bivatuzumab) bound to mertansine was tested in phase I clinical trials for head and neck and esophagus squamous cell carcinomas [285,286] and for breast cancer [287], but the trials had to be terminated before progression to phase II due to severe skin toxicities. This evidence concerns the gene CD44 and breast carcinoma.